Today's fee-for-service oncology business model misaligns incentives by rewarding practices for keeping margins and service volumes high — even when it's wasteful — rather than for optimizing patient outcomes. While discussions of drug pricing dominate the cost control conversation, we, as practitioners, have been abdicating responsibility and missing the opportunity to address cancer's financial toxicity. We can do better. The practice-level assumption of financial risk for patient care — or the ...

Read more...

1 Pages

Most Popular

✓ Join 150,000+ subscribers
✓ Get KevinMD's most popular stories